Physician profile
Ashwin Jathavedam
NPI 1609862747
$2,432.31
in general payments reported to CMS, 2019-2025
29 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,244 · 2020: $268 · 2021: $14.59 · 2022: $59.62 · 2023: $165 · 2024: $414 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $570.63 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $329.20 | 2019-2025 | Gardasil 9, Capvaxive, Dificid |
| Viiv Healthcare Company | $319.57 | 2019-2025 | Apretude, Cabenuva |
| Insmed, INC. | $289.13 | 2019-2025 | Arikayce |
| Abbvie INC. | $113.18 | 2021-2025 | |
| Philips North America LLC | $97.49 | 2024 | (9274) Lld |
| Janssen Biotech, INC. | $94.97 | 2019 | |
| Glaxosmithkline, LLC. | $80.79 | 2019-2025 | Shingrix |
| Allergan, INC. | $79.66 | 2019-2020 | |
| Theratechnologies INC. | $44.33 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $43.16 | 2019 | |
| Melinta Therapeutics, LLC | $43.12 | 2019-2023 | Vabomere, Orbactiv, Kimyrsa |
| Cumberland Pharmaceuticals, INC. | $40.10 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $30.85 | 2019 | |
| Exact Sciences Corporation | $30.35 | 2023 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $28.77 | 2020 | |
| Abbott Laboratories | $24.16 | 2024 | Freestyle Libre |
| Aimmune Therapeutics, INC. | $19.00 | 2025 | Vowst |
| Seqirus USA INC | $17.00 | 2024 | Fluad, Flucelvax |
| Pfizer INC. | $14.77 | 2019 | |
| Vyera Pharmaceuticals, LLC | $14.67 | 2019 | |
| Lilly USA, LLC | $14.47 | 2019 | |
| Bausch Health US, LLC | $14.42 | 2019 | |
| Napo Pharmaceuticals INC | $14.27 | 2019 | |
| Amgen INC. | $13.64 | 2019 | |
| Angiodynamics, INC. | $13.38 | 2019 | |
| Amarin Pharma, INC. | $12.95 | 2019 | |
| Nabriva Therapeutics, Plc | $12.90 | 2020 | |
| Scilex Pharmaceuticals INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Jathavedam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.